# EDGAR Filing Document

**Accession Number:** 0001478982
**File Stem:** 0000902664-26-000237
**Filing Date:** 2026-1
**Character Count:** 22174
**Document Hash:** e0cc11243e612abbfc014e5327785ab6
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000902664-26-000237.hdr.sgml**: 20260115

**ACCESSION NUMBER**: 0000902664-26-000237

**CONFORMED SUBMISSION TYPE**: DFAN14A

**PUBLIC DOCUMENT COUNT**: 7

**FILED AS OF DATE**: 20260115

**DATE AS OF CHANGE**: 20260115

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ORASURE TECHNOLOGIES INC
- **CENTRAL INDEX KEY:** 0001116463
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 364370966
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** DFAN14A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-16537
- **FILM NUMBER:** 26534808

**BUSINESS ADDRESS:**
- **STREET 1:** 220 E FIRST ST
- **CITY:** BETHLEHEM
- **STATE:** PA
- **ZIP:** 18015
- **BUSINESS PHONE:** 5036416115

**MAIL ADDRESS:**
- **STREET 1:** 220 E FIRST ST
- **CITY:** BETHLEHEM
- **STATE:** PA
- **ZIP:** 18015
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Altai Capital Management, L.P.
- **CENTRAL INDEX KEY:** 0001478982

**ORGANIZATION NAME:**
- **EIN:** 270488863
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** DFAN14A

**BUSINESS ADDRESS:**
- **STREET 1:** 9040 SUNSET BLVD #1004
- **CITY:** WEST HOLLYWOOD
- **STATE:** CA
- **ZIP:** 90069
- **BUSINESS PHONE:** 949-326-9611

**MAIL ADDRESS:**
- **STREET 1:** PO BOX 15203
- **CITY:** IRVINE
- **STATE:** CA
- **ZIP:** 92623-9998

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a)

of the Securities Exchange Act of 1934

Filed by the Registrant ◻

Filed by a Party other than the Registrant 🗹

Check the appropriate box:

---

| | |
|:---|:---|
| &nbsp;&nbsp;◻ | &nbsp;&nbsp;Preliminary Proxy Statement |
| &nbsp;&nbsp;◻ | &nbsp;&nbsp;Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
| &nbsp;&nbsp;◻ | &nbsp;&nbsp;Definitive Proxy Statement |
| &nbsp;&nbsp;◻ | &nbsp;&nbsp;Definitive Additional Materials |
| &nbsp;&nbsp;🗹 | &nbsp;&nbsp;Soliciting Material Under Rule 14a-12 |

---

**OraSure Technologies, Inc.**

(Name of Registrant as Specified In Its Charter)

**Altai Capital Management, L.P.**

**Altai Capital Management, LLC**

**Altai Capital Osprey, LLC**

**Rishi Bajaj**

**John Bertrand**

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

🗹 No fee required.

☐ Fee paid previously with preliminary materials.

☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

![](image_004.jpg)

**Altai Capital Management Nominates Two Highly-Qualified Candidates for Election to OraSure Board of Directors**

*Reiterates Urgent Need for Change to Address Company's Failure to Deliver Value to Shareholders*

Los Angeles, CA, - Jan. 15, 2026 -- Altai Capital Management, L.P. ("Altai"), one of the largest shareholders and beneficial owners of approximately 5.2% of the outstanding common stock of OraSure Technologies, Inc. ("OraSure" or the "Company") (NASDAQ: OSUR), today announced that it has nominated two highly-qualified candidates, John Bertrand, Co-Founder of Digital Diagnostics, and Rishi Bajaj, President and CIO of Altai, for election to the OraSure Board of Directors (the "Board") at the 2026 Annual Meeting of Stockholders.

The nomination follows Altai's December 17 letter to the Board outlining its serious concerns about the Company's significant share price underperformance driven by poor strategic and capital allocation decisions by management and the Board's refusal to consider alternative strategies for value creation.

"As long-term OraSure shareholders, we remain firmly convinced in the potential of the Company despite significant underperformance, which we believe has been driven by extremely poor strategy and capital allocation decisions," said Rishi Bajaj. "It has become clear to us that the current Board is neither capable of nor willing to take the necessary steps to transform the Company, and we believe that specialized expertise and direct shareholder perspective is needed to put the Company on a better path forward to deliver substantial near- and long-term value. Both John and I would add the needed expertise and perspective that the current Board lacks, and we look forward to enthusiastically presenting our case and qualifications directly to fellow OSUR shareholders."

***Rishi Bajaj*** 

Mr. Bajaj founded Altai Capital Management, L.P. in 2009 and serves as its President and Chief Investment Officer. He has extensive public company board experience, and brings significant investment management, operational, and technology-sector expertise to his board roles. He currently serves on the Board of Directors of Digimarc Corporation as a member of its Audit Committee, and previously served on the boards of ContextLogic, a publicly traded business ownership platform (including as Chairman and Chief Executive Officer from 2024 to 2025), MobileIron, and ServiceSource International in various committee roles. Previously, he was a Senior Investment Analyst at Silver Point Capital and an M&A and Restructuring Analyst at Gleacher Partners. He holds a B.S. in Economics with concentrations in Finance and Statistics from The Wharton School of the University of Pennsylvania.

***John Bertrand***

Mr. Bertrand co-founded Digital Diagnostics Inc. in 2019 and has served as its Chief Executive Officer, leading the company's evolution from a research-focused organization into a global, commercial artificial intelligence platform for disease diagnosis. Previously, he spent more than 12 years in various roles at Epic Systems Corporation, including as a Business Development and Product Management Executive, where he led cross-functional teams focused on product growth, customer success, and commercialization. He has extensive board and advisory experience across healthcare and technology, currently serving as a Senior Advisor to Bain Capital since 2023, as a Senior Advisor and Executive in Residence at 8VC since 2018, and as a director of KeyCare, Surglogs, Digital Diagnostics, and Sirona Medical, with prior advisory roles at Innovaccer, iRhythm Technologies, Digital Surgery, and Matrix Capital Management. He holds a B.S. in Business Management from Purdue University and brings deep expertise in healthcare technology, artificial intelligence, and scaling innovative products to his director roles.

**About Altai Capital Management** 

Altai Capital Management is a technology-focused investment firm founded in 2009 by Rishi Bajaj. Altai makes long-term investments across a diverse range of financial instruments, including debt, private equity, venture capital, and publicly traded securities. To learn more, visit www.altai.com.

**Disclaimers**

This press release and the opinions herein are for general information only, and are not intended to be, nor should they be construed as, an offer to sell or a solicitation of an offer to buy any security, a recommendation to purchase or sell any security, or legal, financial, tax, investment, or other advice.

Altai Capital Management, L.P., Altai Capital Management, LLC, Altai Capital Osprey, LLC, Rishi Bajaj and John Bertrand (collectively, the "Participants") intend to file with the SEC a definitive proxy statement and accompanying form of proxy to be used in connection with the solicitation of proxies from the stockholders of OraSure Technologies, Inc. Stockholders are advised to read the definitive proxy statement and other documents related to the solicitation of proxies by the Participants when they become available, as they will contain important information, including additional information related to the Participants. The definitive proxy statement and an accompanying proxy card will be furnished to OraSure Technologies, Inc. stockholders and will be, along with other relevant documents, available at no charge on the SEC website at http://www.sec.gov/.

Information about the Participants and a description of their direct or indirect interests, by security holdings or otherwise, is contained in Exhibit 1 to the Schedule 14A filed by the Participants with the SEC on January 15, 2026. This document is available free of charge from the source indicated above.

**Media Contact:**

ASC Advisors<br> Taylor Ingraham / Max Rayden<br> tingraham@ascadvisors.com / mrayden@ascadvisors.com

## Ex-1

**Exhibit 1**

**CERTAIN INFORMATION REGARDING THE PARTICIPANTS**

The Participants (as defined below) intend to file a definitive proxy statement and accompanying form of proxy card with the Securities and Exchange Commission (the "SEC") to be used in connection with the 2026 annual meeting of stockholders of OraSure Technologies, Inc. (the "Company").

The "Participants" in this proxy solicitation are currently: (i) Altai Capital Management, L.P. ("Altai Investment Manager"), (ii) Altai Capital Management, LLC ("IMGP"), (iii) Altai Capital Osprey, LLC, ("Osprey"), (iv) Rishi Bajaj ("Mr. Bajaj") and (v) John Bertrand ("Mr. Bertrand").

As of the date hereof, the Participants may be deemed to beneficially own (within the meaning of Rule 13d-3 under the Securities Exchange Act of 1934, as amended), in the aggregate, 3,740,836 shares of common stock, par value $0.000001 per share, of the Company (the "Common Stock") (including the 100 shares of Common Stock held in record name by Osprey). Of the 3,740,836 shares of Common Stock (including the 100 shares of Common Stock held in record name by Osprey) beneficially owned in the aggregate by the Participants (i) 100 shares of Common Stock are directly owned in record name by Osprey and (ii) 3,740,736 shares of Common Stock are held in certain managed accounts (the "Managed Accounts"). By virtue of being the investment manager of Osprey and the Managed Accounts, Altai Investment Manager may be deemed to beneficially own 3,740,836 shares of Common Stock (including the 100 shares of Common Stock held in record name by Osprey). By virtue of being the general partner of Altai Investment Manager, IMGP may be deemed to beneficially own 3,740,836 shares of Common Stock (including the 100 shares of Common Stock held in record name by Osprey). By virtue of being the President and Chief Investment Officer of Altai Investment Manager, Mr. Bajaj may be deemed to beneficially own 3,740,836 shares of Common Stock (including the 100 shares of Common Stock held in record name by Osprey). Mr. Bertrand does not own any shares of Common Stock.

## Ex-2

![](image_003.jpg)

**Exhibit 2**

December 17, 2025

**<u>VIA EMAIL</u>**

Mr. John P. Kenny

Chairman of the Board

OraSure Technologies, Inc.

150 Webster St.

Bethlehem, PA 18015

CC: Board of Directors of OraSure

Dear Mr. Kenny and Members of the Board:

Altai Capital Management, L.P. ("Altai Capital" or "we") is a beneficial owner of approximately 5.2% of the outstanding common stock of OraSure Technologies, Inc. ("OraSure" or the "Company"), making us one of OraSure's largest shareholders. Since November 2024, we have had several private conversations with OraSure's Board of Directors ("the Board") and management to explore ways to create value for OraSure. Through this dialogue and the subsequent actions of the Company, it is clear to us that the Board remains obstinately committed to the Company's failing strategy in life sciences that has destroyed significant shareholder value across every reasonable metric.

We are now more convinced than ever that the current Board is not capable of taking the necessary steps to transform the Company. **We therefore intend to nominate John Bertrand, CEO of Digital Diagnostics, and myself, Rishi Bajaj, President and CIO of Altai Capital, for election to the Board at the 2026 Annual Meeting of Stockholders**. Please see *Exhibits A* and *B*, respectively, for Mr. Bertrand's and my biographies.

We believe that the causes of the Company's underperformance are primarily driven by extremely poor strategy and capital allocation decisions. First, management failed to execute the steps required to turn around its core product segments amidst its Covid-19 windfall revenue winding down. Second, the Company has squandered millions of dollars making ill-timed venture-like investments in failing, subscale and/or unprofitable companies. Finally, OraSure continues to burn cash in its core product segments with no tangible return on the horizon.

**Price Performance Graph: OraSure vs. Relevant Indices**<sup>1</sup>

![](image_002.jpg)

<sup>_____________________________</sup>

<sup>1</sup> Performance is calculated for the period 12/01/20 – 12/12/25. Data for the Bloomberg US 3000 Life Science & Diagnostics Price Return Index, S&P Health Care Index, NASDAQ Composite Index and the NYSE Composite Index assume reinvestment of dividends.

![](image_003.jpg)

**Price Performance: OraSure vs. Relevant Indices**<sup>2</sup>

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | &nbsp;&nbsp;**5-Year Performance** | &nbsp;&nbsp;**5-Year Performance** | &nbsp;&nbsp;**10-Year Performance** | &nbsp;&nbsp;**10-Year Performance** |
|  | &nbsp;&nbsp;**% Return** | &nbsp;&nbsp;**OraSure vs. Relevant Index** | &nbsp;&nbsp;**% Return** | &nbsp;&nbsp;**OraSure vs. Relevant Index** |
| &nbsp;&nbsp;Bloomberg Life Science & Diagnostics Index | &nbsp;&nbsp;411111&nbsp;&nbsp;% | &nbsp;&nbsp;(83)&nbsp;&nbsp;% | &nbsp;&nbsp;22311111&nbsp;&nbsp;% | &nbsp;&nbsp;(283)&nbsp;&nbsp;% |
| &nbsp;&nbsp;S&P 500 Health Care Index | &nbsp;&nbsp;5211111&nbsp;&nbsp;% | &nbsp;&nbsp;(131)&nbsp;&nbsp;% | &nbsp;&nbsp;15511111&nbsp;&nbsp;% | &nbsp;&nbsp;(215)&nbsp;&nbsp;% |
| &nbsp;&nbsp;NASDAQ Composite Index | &nbsp;&nbsp;9511111&nbsp;&nbsp;% | &nbsp;&nbsp;(175)&nbsp;&nbsp;% | &nbsp;&nbsp;39511111&nbsp;&nbsp;% | &nbsp;&nbsp;(456)&nbsp;&nbsp;% |
| &nbsp;&nbsp;NYSE Composite Index | &nbsp;&nbsp;7611111&nbsp;&nbsp;% | &nbsp;&nbsp;(155)&nbsp;&nbsp;% | &nbsp;&nbsp;17011111&nbsp;&nbsp;% | &nbsp;&nbsp;(230)&nbsp;&nbsp;% |
| &nbsp;&nbsp;**OraSure** | &nbsp;&nbsp;**(80)**&nbsp;&nbsp;**%** |  | &nbsp;&nbsp;**(60)**&nbsp;&nbsp;**%** |  |

---

Adding a motivated, experienced board member with significant stock ownership should be an obvious step in the right direction for any board, especially one with a track record as poor as OraSure's. Yet, the Board has made clear in private conversations that it would not be persuaded by our arguments or give proper consideration to my candidacy. Instead of appointing someone with a meaningful ownership interest who is aligned with shareholders, the Board recently added Stephen Boyd, who is a *former*, not current, shareholder of the Company, with no apparent board, operating or business restructuring experience.

We are not saying that Mr. Boyd is incapable of learning on the job. We are instead emphatically saying that shareholders should not fund Mr. Boyd's education as OraSure attempts to navigate a critical turnaround situation. Despite the Company's so-called board refreshment efforts, OraSure has made no meaningfully positive operational or directional changes. It is transparent to us and many other shareholders that these actions are simply cosmetic and are not intended to take real accountability. As such, we do not believe the Company is committed to responding to its past mistakes through a comprehensive reevaluation of its strategy which is imperative for value creation.

OraSure is at a pivotal moment in its journey and faces significant obstacles ahead. Mr. Boyd's appointment clearly demonstrates that the Board has little respect for the challenges the Company is facing, and little regard for the anger shareholders feel for the way the Company has addressed many of these same challenges in the past. This pattern of disregard for shareholder interests must cease immediately. OraSure has squandered 25% of its cash and cash equivalents balance since Q4 2023 while its quarterly revenue (excluding Covid-19 products) has declined over 20% in the same timeframe. Shareholders like us who are anxious and motivated to drive change deserve better. If the Board does not change course immediately, the risk of permanent capital impairment will continue to increase. Perhaps more importantly, we see little hope that OraSure will outperform relative to its risk.

We and Mr. Bertrand believe there is a better path forward to transform the Company that will deliver substantial near-term and long-term value to all shareholders while mitigating the potential for future value destruction. As we have stated to you numerous times throughout this year, Mr. Bertrand and I stand ready to join the Board immediately and draw upon our collective experience and successful track records to drive value to all shareholders. We look forward to enthusiastically presenting our case directly to shareholders if the Board fails to act. Until then, we remain open to engaging with the Board and management to achieve what should be our shared long-term goal of delivering sustained and enduring value to shareholders.

Sincerely,

![](image_001.jpg)

_____________________

Rishi Bajaj

President & Chief Investment Officer

<sup>_____________________________</sup>

<sup>2</sup> The 5-year and 10-year performance is calculated for the period 12/01/20 – 12/12/25 and 12/01/15 – 12/12/25, respectively. Data for the Bloomberg US 3000 Life Science & Diagnostics Price Return Index, S&P Health Care Index, NASDAQ Composite Index and the NYSE Composite Index assume reinvestment of dividends. OraSure vs. Relevant Index performance figures may not equal the calculated differences due to rounding.

**EXHIBIT A**

**<u>John Bertrand Biography:</u>**

John Bertrand co-founded and has served as the Chief Executive Officer of Digital Diagnostics Inc., a leading health technology company, since 2019. Since co-founding the company, Mr. Bertrand has led the company's transformation from a primarily research-driven organization to a commercial enterprise that acts as a global artificial intelligence platform to diagnose many diseases.

Previously, from 2006 to 2019, Mr. Bertrand served in various roles, including as a Business Development and Product Management Executive, at Epic Systems Corporation, a healthcare software company, where he led cross-functional teams in a variety of product, customer success, and business development roles with a focus on growth.

Mr. Bertrand has served in advisory roles and on the boards of directors of numerous technology companies. Mr. Bertrand has served as a Senior Advisor to Bain Capital, a private investment firm, since 2023, supporting the firm's private equity practice in the healthcare information technology, diagnostics and therapeutics sectors. Mr. Bertrand has served in various roles, including as a Senior Advisor and Executive in Residence, at 8VC, a leading Silicon Valley venture capital firm focused on healthcare technology, since 2018. Mr. Bertrand has served on the Board of Directors of Keycare, Inc., a telehealth platform, since 2022, on the Board of Directors of Surlogs Inc., a regulatory compliance software company, since 2020, on the Board of Directors of Digital Diagnostics Inc., since 2019, and on the Board of Directors of Sirona Medical Inc., a medical software company, since 2019. Previously, Mr. Bertrand served on the Board of Advisors at Innovaccer, Inc., a digital healthcare company, from 2019 to 2020, and on the Board of Advisors at iRhythm Technologies Inc., a digital healthcare company, from 2019 to 2020. From 2018 to 2020, Mr. Bertrand served on the Board of Advisors of Digital Surgery, a health technology company, and from 2016 to 2018, he served on the Board of Advisors at Matrix Capital Management, a hedge fund.

Mr. Bertrand holds a B.S. in Business Management from Purdue University.

Mr. Bertrand's qualifications to serve as a director of the Corporation include over a decade of executive leadership experience in the healthcare technology sector, where he has developed expertise in the application of artificial intelligence and computer vision in healthcare, identifying market opportunities, creating new products, and pivoting existing businesses.

![](image_003.jpg)

**EXHIBIT B**

**<u>Rishi Bajaj Biography:</u>**

Rishi Bajaj founded Altai Capital Management, L.P., a private investment firm, in 2009. He serves as its President and Chief Investment Officer, where he is responsible for the management and operations of the business. From 2024 to 2025, Mr. Bajaj also served as the Chief Executive Officer of ContextLogic Holdings Inc. ("ContextLogic", OTCQB: LOGC).

Prior to founding Altai Capital, Mr. Bajaj served as a Senior Investment Analyst at Silver Point Capital, L.P., a private investment management firm, from 2003 to 2009, and as an M&A and Restructuring Analyst at Gleacher Partners, LLC, an M&A advisory firm, from 2001 to 2003.

Mr. Bajaj has served on the Board of Directors of Digimarc Corporation ("Digimarc", NASDAQ: DMRC), a digital watermarking company, since July 2025. He is currently a member of Digimarc's Audit Committee. Mr. Bajaj previously served (i) on the Board of Directors of ContextLogic from 2023 to 2025, where he served as Chairman, from 2024 to 2025, as well as a member of the Compensation Committee and Transformation Committee, (ii) on the Board of Directors of MobileIron, Inc. (NASDAQ: MOBL, formerly), a cybersecurity company, in 2020, where he served on the Strategy Committee, and (iii) on the Board of Directors of ServiceSource International, Inc. (NASDAQ: SREV, formerly), a software and services company, from 2014 to 2016, where he served on the Compensation Committee.

Mr. Bajaj holds a B.S. in Economics with concentrations in Finance and Statistics from The Wharton School at the University of Pennsylvania.

Mr. Bajaj's qualifications to serve as a director of the Corporation include his years of service on public company boards and his extensive investment management experience and operational expertise, particularly in the technology sector.